Pegulicianine / DVS

About Lumicell

Lumicell is a pioneering oncology surgery company that has achieved a significant milestone with FDA approval of its integrated drug-device system for real-time detection of residual breast cancer during lumpectomy. The company's technology platform utilizes a fluorescent imaging agent and a handheld probe to help surgeons identify and excise cancerous tissue that would otherwise be left behind, potentially reducing re-operation rates and improving patient outcomes. With its first product commercially launched in the U.S., Lumicell is now executing its go-to-market strategy while exploring expansion into other solid tumor indications like gastrointestinal cancers. The company is privately held and based in Needham, Massachusetts.

Therapeutic Areas